Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: a case report and literature review
- 15 December 2025
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10 (1)
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory demyelinating disease primarily affecting the optic nerves and spinal cord. Polymyositis (PM) is an idiopathic inflammatory myopathy characterized by proximal muscle weakness. The anti-signal recognition particle (SRP) antibody is a myositis-specific autoantibody. We herein present a case of anti-SRP antibody-positive PM that developed 6 years after the onset of NMOSD. A 52-year-old woman was diagnosed with NMOSD 6 years previously based on left visual disturbance, a high signal intensity and contrast enhancement of the optic nerve on short τ inversion recovery (STIR)-magnetic resonance imaging (MRI), and anti-aquaporin 4 antibody positivity. She received methylprednisolone pulse therapy followed by oral prednisolone (PSL) at a starting dose of 40 mg daily. Three years later, due to recurrent numbness in the left lower limb and difficulty in reducing the PSL dose to ≤10 mg/day, satralizumab was initiated. At 52 years old, she developed myalgia and muscle weakness in both thighs. PM was diagnosed based on an elevated serum creatine kinase level, anti-SRP antibody positivity, high signal intensities in the right triceps and bilateral adductor muscles on STIR-MRI, and muscle biopsy findings. Treatment with high-dose PSL and tacrolimus markedly attenuated her symptoms. Satralizumab was continued for NMOSD stabilisation. Previous studies reported the coexistence of NMOSD and autoimmune diseases; however, NMOSD with PM/DM is rare. We described a case of NMOSD with anti-SRP antibody-positive PM and provided a literature review.Keywords
This publication has 43 references indexed in Scilit:
- The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implicationsBiomedicine & Pharmacotherapy, 2025
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term managementJournal of Neurology, 2023
- Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum DisorderAnnals of Neurology, 2023
- Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and DermatomyositisACR Open Rheumatology, 2022
- Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanomaMultiple Sclerosis and Related Disorders, 2019
- The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic reviewClinical Rheumatology, 2015
- Dermatomyositis as a presentation of neuromyelitis optica spectrum disorderJournal of Neuroimmunology, 2015
- Fulminant myelitis with NMO IgG antibody following treatment with interferon alphaJournal of Neurology, 2013
- Interleukin‐6 and type I interferon–regulated genes and chemokines mark disease activity in dermatomyositisArthritis & Rheumatism, 2009
- IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositisJournal of Neuroimmunology, 2006